SCHEMBL3215905

SCHEMBL3215905

O=C(O)NS(=O)(=O)NCCNc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CA12 O43570 5/20 0.41
CA9 Q16790 4/20 0.41
CA2 P00918 3/20 0.41
CA1 P00915 3/20 0.40
EPHX1 P07099 1/20 0.40
ACP1 P24666 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CA7 P43166 2/20 0.38
CA14 Q9ULX7 2/20 0.38
HDAC6 Q9UBN7 1/20 0.37
GAA P10253 1/20 0.37
RORC P51449 1/20 0.36
LMNA P02545 1/20 0.36
DRD4 P21917 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3209241 0.77 CA12 (0.60) ALDH1A1MAPTMEN1KMT2ACA12
Methane SCHEMBL11118664 0.77 ALDH1A1 (0.48) ALDH1A1MAPTMEN1KMT2ACA12
SCHEMBL632638 0.74 POLB (0.55) ALDH1A1MAPTMEN1KMT2ACA12
Sulfuric Acid SCHEMBL8070176 0.74 POLB (0.50) ALDH1A1MAPTMEN1KMT2ACA12
SCHEMBL3565228 0.74 EPHX1 (0.54) ALDH1A1MAPTEPHX1L3MBTL1HDAC6
SCHEMBL7086468 0.74 KEAP1 (0.50) ALDH1A1MEN1KMT2ACA12CA9
SCHEMBL3195576 0.73 MTNR1A (0.53) ALDH1A1MEN1KMT2AL3MBTL1DRD4
SCHEMBL6993873 0.73 CA12 (0.70) MAPTMEN1KMT2ACA12CA9
Sulfuric Acid SCHEMBL8822471 0.72 POLB (0.49) ALDH1A1MAPTMEN1KMT2ACA12
Sulfuric Acid SCHEMBL8645602 0.72 POLB (0.49) ALDH1A1MAPTMEN1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041892-A1 Therapeutic agent for diabetes ABE HIDENORI 2010-02-18 US disclosed
US-20090270631-A1 Therapeutic agent for diabetes ABE HIDENORI 2009-10-29 US disclosed
US-20080009530-A1 Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270631-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 212/4885MAPT 4588/4885MEN1 3927/4885
US-20080009530-A1 Therapeutic Agent for Diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 118/4885MAPT 4612/4885MEN1 3517/4885
US-20100041892-A1 Therapeutic agent for diabetes FABP4, SLC5A1, SLC5A2 ALDH1A1 212/4885MAPT 4588/4885MEN1 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.